Research & White Papers

New Market Opportunities for mAbs

Monoclonals Revolutionizing Pathogen Treatments

Natural Killer Cells

The Promise of NK Cells and 3 Strategies for Creating a Cost-Effective Program

Eliminating Downstream Bottlenecks

Eliminating Downstream Bottlenecks and Boosting Productivity in Antibody-Based Therapies

Allogeneic Cell Therapy

Opportunities to Accelerate Allogeneic Cell therapy Production

Scale-Down Models

Get to GMP Clinical Stage Quickly Utilizing Scaled-Down Models in Viral Vector Production

Large-Scale AAV Manufacturing

Manufacturing Large-Scale AAV From Concept to Ready-to-Use Platform

Custom Viral Vectors

Like a Tailored Suit: Producing Customized Viral Vectors that Respond to Market Demands

Mammalian Large-Scale Commercial Manufacturing

Q&A: Outsourcing Mammalian Development & Large-Scale Commercial Manufacturing

pDNA Upstream Optimization

The Future of Plasmid DNA Upstream Optimization

PPQ Assessment

Assess Reliability, Confidence, Inter & Intra Batch Variation Uncertainties in PPQ Sample Size Selection

mRNA Custom Program

mRNA: How to Build a Custom Program Using CDMO Services

cGMP Compliance

cGMP Compliance in a Growing Biologics Market

Webinar: Cell Line Development

On-demand webinar: Accelerating Cell Line Development from DNA to Master Cell Bank

Webinar: Large-Scale AAV Manufacturing

On-demand webinar: The Future of Plug-and-Play Large-Scale AAV Manufacturing